Glucose control of glucagon secretion—‘There’s a brand-new gimmick every year’

Erik Gylfe

To cite this article: Erik Gylfe (2016) Glucose control of glucagon secretion—‘There’s a brand-new gimmick every year’, Upsala Journal of Medical Sciences, 121:2, 120-132, DOI: 10.3109/03009734.2016.1154905

To link to this article: http://dx.doi.org/10.3109/03009734.2016.1154905

© 2016 The Author(s). Published by Taylor & Francis.

Published online: 04 Apr 2016.

Submit your article to this journal

Article views: 422

View related articles

View Crossmark data
Glucose control of glucagon secretion—‘There’s a brand-new gimmick every year’

ERIK GYLFE
Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden

ABSTRACT
Glucagon from the pancreatic α-cells is a major blood glucose-regulating hormone whose most important role is to prevent hypoglycaemia that can be life-threatening due to the brain’s strong dependence on glucose as energy source. Lack of blood glucose-lowering insulin after malfunction or autoimmune destruction of the pancreatic β-cells is the recognized cause of diabetes, but recent evidence indicates that diabetic hyperglycaemia would not develop unless lack of insulin was accompanied by hypersecretion of glucagon. Glucagon release has therefore become an increasingly important target in diabetes management. Despite decades of research, an understanding of how glucagon secretion is regulated remains elusive, and fundamentally different mechanisms continue to be proposed. The autonomous nervous system is an important determinant of glucagon release, but it is clear that secretion is also directly regulated within the pancreatic islets. The present review focuses on pancreatic islet mechanisms involved in glucagon regulation of glucagon release. It will be argued that α-cell-intrinsic processes are most important for regulation of glucagon release during recovery from hypoglycaemia and that paracrine inhibition by somatostatin from the δ-cells shapes pulsatile glucagon release in hyperglycaemia. The electrically coupled β-cells ultimately determine islet hormone pulsatility by releasing synchronizing factors that affect the α- and δ-cells.

Introduction
After Paul Langerhans’s discovery of the pancreatic islets in 1869 (1), Diamare found in 1899 that they contain two types of cells (2), which Lane in 1907 designated as α- and β-cells (3) (later also A and B cells). In 1915 Homans predicted that the B cells are the origin of ‘an internal secretion vital to the utilization of dextrose’ (4), and the glucose-lowering hormone, insulin, was discovered by Banting and Best in 1921 (5). In 1923 Murlin et al. observed that pancreatic insulin extracts sometimes were contaminated with a hyperglycaemic factor (6) that was named glucagon (7), whose production was eventually linked to the α-cells by Sutherland and De Duve in 1948 (8). Claes Hellerström, who is honoured in the current issue of this journal, made significant contributions in the glucagon field in his early scientific career. Together with his mentor Bo Hellman, Hellerström invented a silver impregnation technique that revealed A cell heterogeneity (9). The silver-positive and -negative A cells were named A1 and A2, respectively. They also provided indirect evidence that glucagon originates from the A2 cells by showing that they undergo pronounced nuclear atrophy after glucagon injections (10). Hellerström later pioneered studies of glucagon biosynthesis in guinea pig islets (11) as well as studies of metabolism (oxygen consumption) in A cell-enriched islets from streptozotocin-diabetic guinea pigs (12). Hellman and Lenmark showed that the A1, or A2, cells, which later proved to be identical to the D cells defined by Bloom in 1931 (13), secrete a factor that inhibits insulin secretion (14). This D cell (δ-cell) factor was later identified as somatostatin (15). There is still some confusion with regard to the use of the Greek or Latin designations, but the glucagon-producing cells are nowadays mostly referred to as α-cells and those secreting insulin and somatostatin as β- and δ-cells, respectively, which is the nomenclature subsequently used in this review.

With the discovery of insulin, life-saving treatment of diabetic patients rapidly became possible (16). It is consequently not surprising that most research has been focused on insulin and its actions in the search for improved strategies for optimizing blood glucose control and preventing secondary diabetes complications. Although it has become increasingly clear that hypersecretion of glucagon contributes to hyperglycaemia in diabetes (see (17) for review), it may have surprised many when the Unger group provided evidence that lack of insulin does not lead to diabetes in mice if the blood glucose-elevating effect of glucagon is prevented (18,19). However, disruption of glucagon action/secretion did not improve glucose tolerance in diabetic mice in another study (20).

Whereas diabetic hyperglycaemia may persist undetected for long periods of time, severe hypoglycaemia is acutely life-threatening due to the brain’s strong dependence on glucose as energy source. Glucagon is the major glucose counter-regulatory hormone, and its physiologically most important role is to prevent hypoglycaemia. Glucagon secretion is consequently stimulated when the blood sugar concentration falls below the resting level. Unfortunately, also this...
mechanism is compromised in diabetes (21), implying deteriorated recovery from dangerous hypoglycaemia that may occur accidentally in patients subjected to aggressive glucose-lowering treatment to reduce diabetes complications. Being essential for survival and well-being, the release of insulin and glucagon is controlled by multiple direct and indirect mechanisms. The blood glucose concentration is e.g. monitored by glucose-sensing cells in the portal vein area and in different regions of the brain, resulting in parasympathetic stimulation of insulin release in hyperglycaemia and glucagon release in hypoglycaemia, as well as sympathetic inhibition of insulin and stimulation of glucagon secretion in hypoglycaemia (22,23). However, the contribution of neural influence may differ between species since human islets are less innervated than rodent islets (24). Moreover, it is clear that glucose control of insulin and glucagon secretion persists in the perfused pancreas and isolated pancreatic islets. The subsequent focus will be on the glucose regulation of glucagon release that occurs within the pancreatic islets.

Already 30 years ago there was a unifying theory how the β-cells recognize glucose and the subsequent signalling that triggers release of insulin (25). The major aspects of the so-called consensus hypothesis are still valid and imply that glucose is rapidly taken up by the β-cells and metabolized to generate ATP. The resulting increase of the ATP/ADP ratio closes ATP-sensitive K⁺ (KATP) channels to depolarize the β-cell and open voltage-dependent L-type Ca²⁺ channels. Subsequent influx of Ca²⁺ raises the cytoplasmic Ca²⁺ concentration ([Ca²⁺]), which is the most important trigger of insulin release. This model consequently implies that the β-cells have an intrinsic capacity to sense glucose and release insulin as required, but [Ca²⁺]-triggered secretion can also be enhanced or reduced by increase or decrease of cAMP, as well as by modulation of protein kinase C and the protein phosphatase calcineurin, mediated by paracrine effects of α-cell glucagon, δ-cell somatostatin and neurotransmitters like acetylcholine and noradrenaline (26,27).

The understanding of how glucose regulates glucagon secretion from the α-cells has progressed much more slowly, and it is remarkable that fundamentally different mechanisms continue to be proposed. Although Ca²⁺ and cAMP are generally believed to have similar secretion-triggering and -amplifying functions for glucagon as for insulin secretion (28–33), recent data indicate that glucagon release may sometimes be controlled independently of [Ca²⁺] (34–36). Lack of paracrine inhibition of the α-cells is often considered to underlie glucagon hyperssecretion in diabetic hyperglycaemia, and paracrine factors have also been implicated in glucose control of glucagon secretion in hypoglycaemia. However, the spectrum of putative paracrine factors released from adjacent islet cells clearly differs under hypo- and hyperglycaemia due to specific glucose sensitivities of the different islet cell types (Figure 1). This review will therefore consider how glucose controls glucagon secretion by α-cell interactions with other islet cells as well as by α-cell-intrinsic mechanisms that contribute differently depending on the prevailing glucose concentration (Figure 2). The present contribution extends and updates a previous review with similar focus on glucose (37), but is more limited than another review (38) with regard to other modulators of glucagon release.

**Autocrine amplification of glucagon release**

Mouse and human pancreatic islets exposed to hypoglycaemic conditions increase their release of glucagon with maximal effect in the complete absence of sugar (39–41), although there should be less energy available to fuel α-cell secretion under such conditions. Positive feedback has been
proposed to potentiate secretion in this situation and to explain how relatively modest changes in blood glucose can guarantee appropriate regulation of glucagon release (42). Indeed, glucagon has been found to amplify its own secretion by raising α-cell cAMP (32,33), and glutamate co-released with glucagon can promote secretion by raising [Ca2+]i after autocrine activation of AMPA/kainate receptors (42).

**Paracrine control of glucagon release**

**Inhibition by β-cell factors**

Insulin released from the β-cells was first proposed (43) and is still considered as a putative mediator of glucose-inhibited glucagon secretion (18,44). Insulin may activate ATP-sensitive K+ (KATP) channels to hyperpolarize the α-cells and close voltage-dependent Ca2+ channels (45), increase the expression of inhibitory γ-aminobutyric acid (GABA) A receptors (see below) (46), or induce cAMP degradation after activation of phosphodiesterase 3B (44). Other studies proposed that Zn2+ co-released with insulin mediates the inhibition (47,48), which involves KATP channel activation and hyperpolarization of the α-cells (45,49). Release of ATP from the secretory granules has also been implicated in paracrine inhibition of α-cell Ca2+ signalling and glucagon secretion from mouse islets (50). Despite an anticipated Ca2+-elevating effect of ATP, this inhibition of secretion was somehow proposed to involve activation of P2Y1 purinoceptors. This finding is contradicted by the observation in rat islets that blockade of this receptor inhibits rather than stimulates glucagon release (51). Other putative inhibitory β-cell-derived messengers are GABA (52) and its metabolite γ-hydroxybutyric acid (GHB) (53). GABA, which inhibits glucagon release by activating a hyperpolarizing Cl− influx in α-cells (52), is present in β-cell synaptic-like microvesicles and insulin-containing granules that undergo exocytosis in response to glucose stimulation (54,55). However, there is also non-vesicular GABA (55,56), and total release was actually reported to be inhibited by glucose (56). GHB, whose release by an unknown mechanism is stimulated by glucose, acts on putative inhibitory receptors on the α-cells (53).

Most evidence that paracrine β-cell factors mediate glucose inhibition of glucagon release comes from experiments comparing hypoglycaemic (<3 mM) and hyperglycaemic (>8 mM) concentrations of glucose. However, maximal inhibition of glucagon release from mouse and human islets is reached already at 5–7 mM glucose (39–41), which corresponds to normal glycaemia in these species (Figure 1). A general problem with the idea that glucose-induced release of insulin and factors co-released with insulin mediate inhibition of glucagon secretion is that insulin release from mouse islets is only stimulated by glucose concentrations higher than 5–7 mM (Figure 1) (39–41). Although the human threshold for insulin secretion is somewhat lower (41), glucagon release is regulated by glucose also below this threshold. Exogenously administered insulin has nevertheless been found to inhibit glucagon secretion from human islets exposed to 1 mM glucose (41), but an insulin receptor antagonist had no effect on glucagon secretion from mouse islets exposed to 3 mM glucose (36). If basal insulin release affects glucagon secretion under hypoglycaemic conditions its role may be permissive rather than regulatory. It cannot be excluded that release of a putative inhibitory β-cell factor is controlled by lower glucose concentrations than those regulating insulin secretion. However, evidence is currently lacking that β-cell exocytosis of different types of vesicles shows separate glucose dependencies (54). The possibility remains that non-vesicular release of inhibitory factors may be controlled by glucose concentrations lower than those triggering exocytosis. In the case of GABA, such control does not seem to mediate inhibition of glucagon secretion. As mentioned above, total GABA release is inhibited rather than stimulated by glucose (56). While 5 mM glucose was found to stimulate GHB release from human islets (53), it remains to be established if secretion is differently regulated than that of insulin, since this glucose concentration is above the threshold for insulin secretion from human islets.

There are obviously reasons to doubt that inhibitory β-cell factors mediate glucose regulation of glucagon in hypoglycaemia. However, the involvement of these factors in direct control of glucagon secretion in hyperglycaemia is also questionable. Studies of human (57) and mouse (58) islets exposed to 20 mM glucose have revealed that insulin and glucagon are released in pulses that are synchronized in opposite phase (Figure 3). Such synchronization apparently explains why the circulating concentrations of the two hormones also

![Figure 3](image_url)
Stimulation by β-cell factors

A paracrine β-cell influence on the α-cells is necessarily not only inhibitory. The dose–response relationship for glucose-regulated glucagon release from mouse and human islets does not show monotonous inhibition. Maximal inhibition of glucagon release is obtained by raising glucose to 5–7 mM, and at higher concentrations the inhibition is gradually reduced (39–41). Concentrations above 20 mM even stimulate glucagon secretion from mouse islets (39). This U-shaped glucose concentration dependence indicates involvement of both inhibitory and stimulatory effects of glucose (Figure 1). The stimulatory component has been attributed to insulin based on the observation that this hormone stimulates rather than inhibits glucagon release from human islets exposed to 6 mM glucose (41), but studies with a receptor antagonist indicated that insulin is inhibitory (44) or lacks effect (36) on glucagon release under hyperglycaemic conditions. ATP from the insulin secretory granules and adenosine formed by extracellular ATP degradation are other putative amplifiers of glucagon secretion. The well-established stimulatory effect of adenosine is mediated by cAMP-elevating A2 receptors (50,61,62), whereas direct ATP actions on Ca²⁺-elevating P2Y₁ purinoceptors have been claimed either to stimulate (51) or to inhibit (50) glucagon release. A particularly interesting aspect of P2Y₁ purinoceptor signalling is that it can mediate synchronization of the insulin secretion-generating [Ca²⁺]₀ oscillations among dispersed β-cells (63) and pancreatic islets (64) that lack physical contact. ATP released from the electrically coupled β-cells within an islet and acting on P2Y₁ purinoceptors on non-coupled α-cells may well explain the above-mentioned paradoxical synchronization of Ca²⁺ oscillations between β- and α-cells (36). It seems possible that more than one inhibitory mechanism may be required to suppress glucagon secretion under hyperglycaemic conditions. General conclusions based on commonly used experimental conditions may consequently overemphasize paracrine β-cell factors in the direct control of glucagon release in general and during hypoglycaemia in particular. It is therefore reassuring that some recent studies focus on regulation of glucagon secretion in recovery from hypoglycaemia by studying the 0–7 mM glucose range (31,39,41,65).

Inhibition by somatostatin from δ-cells

Somatostatin from the δ-cells is a potent inhibitor of both insulin and glucagon release and was early proposed as a paracrine regulator of glucagon release (66) mediating the inhibitory effect of hyperglycaemia (67). Preferential inhibition of glucagon release follows from the higher α- than β-cell sensitivity to somatostatin (68), probably reflecting somatostatin receptor (SSTR) subtype differences with SSTR2 dominating in rodent and human α-cells, and SSTR1 and SSTR5 in human and rodent β-cells, respectively (69–71). The closer spatial association between δ- and α-cells than that between δ- and β-cells in mouse islets (72) may also contribute to the preferential effect on glucagon secretion in this species. Somatostatin acts by reducing adenylyl cyclase production of cAMP via the Gαs subunit coupled to the SSTR2 (44) and by de-priming the glucagon secretory granules after activation of the serine/threonine protein phosphatase calcineurin (73). Compared to β-cell factors, a conceptual advantage of somatostatin-mediated glucagon inhibition of glucagon release is that it may operate also in hypoglycaemia, since glucose stimulates somatostatin release from mouse and human islets at similar concentrations that inhibit glucagon secretion (Figure 1) (39–41). Indeed, blockade of the α-cell SSTR2 (40), perturbation of Gαs signal transduction by pertussis toxin treatment, or knockout of the somatostatin gene (65) enhances glucagon secretion from mouse islets exposed to 0, 1, or 7 mM glucose. However, these conditions do not prevent glucose elevation from inhibiting glucagon secretion. Pertussis toxin treatment also did not prevent inhibition of glucagon secretion from mouse islets in response to a 1 to 20 mM glucose increase (74), but in another study such treatment eliminated the inhibitory effect of a 1 to 11 mM glucose elevation by increasing secretion at the higher concentration (44). In human islets SSTR2 blockade had no effect on glucagon release at either 1 or 6 mM glucose (41), but in another study SSTR2 blockade prevented glucose inhibition by stimulating glucagon secretion at 11 mM but not at 1 mM glucose (44). On the other hand, pertussis toxin treatment eliminated glucose inhibition of glucagon release from human islets by inhibiting secretion at 1 mM but with no effect at 6 mM glucose (41). Taken together, these studies offer meagre support that somatostatin mediates glucose inhibition of glucagon release in the 0–7 mM range, and three studies concluded that the effect of somatostatin is tonic rather than regulatory (40,65,74).

The studies with SSTR2 blockade or pertussis toxin treatment provided conflicting results regarding involvement of somatostatin in glucose inhibition of glucagon release under hyperglycaemic conditions with 11 or 20 mM glucose (44,74). Tolbutamide, which like glucose acts by closing KATP channels to depolarize islet cells, stimulates the release of both insulin (25) and somatostatin (75) and inhibits glucagon release from islets exposed to 1 mM glucose (65). However, tolbutamide becomes stimulatory in pertussis toxin-treated islets, or in...
those from somatostatin knockout mice, and is also stimulatory when glucagon release is already inhibited by exposure to 7 mM glucose (65). Together with observations that glucose concentrations in the 0–20 mM range stimulate glucagon release from purified rat and mouse α-cells (76–78), these data indicate that the direct effect of K*ATP* channel closure in α-cells is stimulatory (see below) and that this stimulation is counteracted by the simultaneously enhanced release of inhibitory somatostatin. Further evidence for a role of somatostatin in the regulation of glucagon secretion in hyperglycaemia is obtained from the kinetics of secretion. Pulsatile hormone release from human and mouse islets is generated by hyperglycaemia with coinciding pulses of insulin and somatostatin that are synchronized in opposite phase to the glucagon pulses (57,58). This relationship is consistent with the possibility that somatostatin peaks generate the nadirs of pulsatile glucagon release. Since pulsatile glucagon release is paradoxically synchronized in opposite phase to the α-cell oscillations of [Ca**2**⁺]**], (discussed above), such a role requires that somatostatin inhibits glucagon release when [Ca**2**⁺]**] is peaking. This may well be the case since SSTR2 blockade potently amplifies glucagon release from mouse islets exposed to 20 mM glucose without marked effects on the [Ca**2**⁺]**] oscillations in α-cells (36). Despite somatostatin’s documented potency as inhibitor of glucagon release (68) and the fact that its secretion increases concentration-dependently up to 30 mM glucose (Figure 1), its paracrine action does not prevent that inhibition of glucagon release from mouse and human islets is gradually diminished in the 7–20 mM range (40,41). The time-average rate of pulsatile glucagon secretion at 20 mM glucose actually represents a rather modest inhibition compared to secretion at 3 mM glucose (57,58).

**Juxtacrine control of glucagon release**

Cells in direct contact often communicate by interactions between surface-bound ephrin and Eph molecules that function as ligands and receptors, or both, and can mediate bidirectional signalling to control cellular functions (79). Eph molecules are tyrosine kinase receptors activated by ephrin. ‘Forward’ signalling from β-cell ephrinA ligand to β-cell EphA receptors has been found to inhibit insulin release by promoting polymerization of an actin network beneath the plasma membrane, whereas ‘reverse’ signalling from EphA to ephrinA promotes secretion by actin depolymerization (80). Glucose amplification of forward signalling from β-cell ephrinA to α-cell EphA4 receptors was recently proposed to complement paracrine inhibition of glucagon release (Figure 2) and explain glucagon hypersecretion when β-cells disappear in diabetes (78). The most compelling argument for such ‘juxtacrine’ control of glucagon release is that artificial activation of forward signalling by exposure to IgG-fused ephrinA molecules restores characteristic glucose inhibition of glucagon release from purified α-cells, which otherwise respond with stimulated secretion (78). The proposed model with juxtacrine β-cell control of glucagon secretion from α-cells is interesting, but available data are limited and further studies are required to pinpoint whether the effects are regulatory or permissive.

Apart from shedding light on the regulation of glucagon release, juxtacrine mechanisms may perhaps help to explain considerable differences in glucose-regulated [Ca**2**⁺]**] signalling between isolated α-cells (81) and those located in their natural environment within pancreatic islets (36).

**β-Cell intrinsic glucose control of glucagon release**

According to the consensus model for glucose-induced insulin release (see above), metabolism of glucose is essential for β-cell recognition of the sugar as stimulus. Considering that hormone secretion is glucose-regulated also in islet α- and δ-cells and that these cell types originate from a common progenitor (82), it seems likely that glucose might be sensed by similar cellular mechanisms. Indeed, glucose metabolism has a central role in different models of α-cell-intrinsic glucose regulation of glucagon release. Glucose transport into rodent β-cells is mediated by the high-**Km** GLUT1 (83), which seems tailored for sensing blood glucose in hyperglycaemia. From this point of view it is natural that rodent α-cells, which are expected preferentially to sense glucose in hypoglycaemia, express the low-**Km** GLUT1 transporter (84,85). However, human β-cells that sense higher concentrations also express the low-**Km** GLUT1 (83), and glucose transport is not rate-limiting for its metabolism since it has been estimated to be 5- to 10-fold higher than glucose utilization in both α- and β-cells (84,85). The high-**Km** glucokinase, which is the dominating glucose-phosphorylating enzyme, is instead the rate-limiting glucosensor in β-cells (86) and may have this function also in α-cells with similar glucokinase activity (85). There is also some α-cell expression of low-**Km** hexokinase, but its significance is unclear, since this enzyme is saturated already by 1 mM glucose (85). The subsequent glycolytic flux is comparable in β- and α-cells (84), but glucose oxidation is considerably lower in α-cells (87,88) and the oxidative phosphorylation less efficient due to high expression of uncoupling protein 2. These differences are reflected by much smaller glucose-induced changes of ATP (36,47,89), FAD (90), and NAD(P)H (91) in α- than in β-cells. Glucose metabolism is nevertheless essential since a non-metabolizable glucose transport analogue has no effect, whereas glucokinase activation mimics glucose inhibition of glucagon release (65). If glucose metabolism in α- and β-cells controls glucagon and insulin release in hypo- and hyperglycaemia, respectively, it might be reflected by a relatively left-shifted dependence of metabolism on the glucose concentration in the α-cell. This seems to be the case since a 1 to 5 mM glucose elevation causes comparable ATP elevation in α- and β-cells, whereas the β-cell response is much greater after further elevation to 20 mM (36).

There are significant differences in the electrophysiology between β- and α-cells. In accordance with the secretory patterns the β-cells become electrically active and show [Ca**2**⁺]**] oscillations at high glucose, whereas the α-cells are active in the absence of the sugar. Glucose-induced closure of the K*ATP* channels depolarizes the β-cells to open L-type Ca**2**⁺ channels that show half-maximal activation at −19 mV, and this Ca**2**⁺ permeability dominates the upstream of the action potentials in the β-cell (25). It is more complex in α-cells with T-type
Ca$^{2+}$ channels that activate at potentials as low as -60 mV and tetrodotoxin (TTX)-sensitive Na$^+$ channels that open at potentials more positive than -30 mV (28,29). There are also L-type and perhaps N-type Ca$^{2+}$ channels in α-cells (30), although studies with more specific inhibitors indicated that the latter channels might be of P/Q-type (31). Whereas Ca$^{2+}$ influx through the L-type channels triggers insulin release from β-cells, the relationship between Ca$^{2+}$ influx into α-cells and glucagon release is more complicated. In rodent α-cells L-type channels dominate (80%) and mediate most Ca$^{2+}$ influx, but their blockade has little effect on secretion. Conversely, blocking the non-L-type channels (20%) has modest effects on [Ca$^{2+}$], but inhibits secretion to a similar extent as glucose elevation from 1 mM to 6 or 7 mM (30,31,92). The greater importance of the non-L-type channels is attributed to their close association with the glucagon-secretory granules (31,93). In the presence of adrenaline, which depolarizes α-cells, mobilizes Ca$^{2+}$ from the endoplasmic reticulum (ER) (81,94), and elevates cAMP (33), entry of extracellular Ca$^{2+}$ through the L-type channels triggers exocytosis of glucagon granules that do not co-localize with these channels (31,95). In human α-cells P/Q-type channels dominate over L-type channels (70%/20% of the integrated Ca$^{2+}$ current) and account for most of the exocytosis, although they open very briefly and only mediate a fraction of the Ca$^{2+}$ entry (96). The fact that glucose inhibition of glucagon release is associated with a rather modest reduction of [Ca$^{2+}$]$_i$ signalling (36,81,91,97,98) is consistent with the idea that Ca$^{2+}$ channels close to the glucagon granules are most important. The background of additional Ca$^{2+}$ entry may perhaps explain why glucose inhibition of glucagon release is far from complete and has a much lower dynamic range than glucose stimulation of insulin release (39–41).

**KATP channel-dependent glucose inhibition of glucagon release**

According to the consensus hypothesis for glucose-stimulated insulin release, ATP acts by blocking K$_{ATP}$ channels to depolarize the β-cell (see above). The most cited model for α-cell intrinsic regulation assumes the same sequence of events, meaning that glucose inhibits glucagon release by depolarizing the α-cells (31,41,93,99–101). The model is somewhat counterintuitive since it nevertheless incorporates the general acceptance that depolarization-induced influx of Ca$^{2+}$ into the α-cells triggers glucagon secretion. The background to this riddle is that the α-cell K$_{ATP}$ channel activity is almost maximally inhibited even in the absence of glucose (41) and that triggering of glucagon secretion by activation of high-threshold P/Q Ca$^{2+}$ channels requires opening of low-threshold T-type Ca$^{2+}$ and Na$^+$ channels (28,91). ATP produced in response to glucose elevation closes the remaining K$_{ATP}$ channels to depolarize the α-cells slightly and inactivate the low-threshold T-type Ca$^{2+}$ and Na$^+$ channels. In this situation the action potential amplitude is reduced and fails to activate secretion-triggering Ca$^{2+}$ influx through the P/Q channels despite [Ca$^{2+}$], elevation by activated L-channels (Figure 4). An implication of the model is that the action potentials that underlie glucagon secretion can only be generated in a narrow membrane potential window, sufficiently depolarized to activate the T-type Ca$^{2+}$ channels and at the same time sufficiently hyperpolarized to prevent their inactivation as well as that of the TTX-sensitive Na$^+$ channels (92). The presence of a narrow membrane potential window is supported by observations that slight depolarization by elevation of the K$^+$ concentration mimics the inhibitory effect of glucose (100) and slight hyperpolarization with low concentrations of K$_{ATP}$ channel-activating diazoxide can reverse glucose inhibition of glucagon secretion from batch-incubated islets (92,99), but such reversal could not be reproduced when measuring glucagon secretion from perfused islets (65). The observation that depolarization by complete K$_{ATP}$ channel closure with tolbutamide inhibits glucagon release has also been taken to support the model (31,41). However, another study argued that increased release of somatostatin from the δ-cells mediates this inhibition, since tolbutamide strongly stimulated glucagon release from somatostatin knockout islets (65). The unexpected observation in normal mouse islets that a high concentration of tolbutamide enhances glucagon release, which has been inhibited by presence of 7 mM glucose, may

**Figure 4.** K$_{ATP}$ channel-dependent regulation of glucagon secretion. In this model only a small fraction of the Ca$^{2+}$ that enters the α-cells triggers glucagon release, and sustained depolarization inhibits secretion by reducing action potential amplitude. The upper left action potential illustration indicates the ion permeabilities that contribute to the different phases, and the lower panel shows these channels in an α-cell. Under stimulatory low-glucose conditions, the T-type Ca$^{2+}$ channels fire spontaneously from about –60 mV and cause a depolarization (ΔV) that activates TTX-sensitive Na$^+$ channels (Na$_v$), which in turn activate L-type and briefly P/Q-type Ca$^{2+}$ channels (pink peaks of the action potentials). The P/Q-type channels are more important for secretion than the L-type channels since the P/Q channels are located closer to the secretory granules. Repolarization depends on activation of voltage-dependent K$^+$ channels (K$_V$). Glucose inhibits glucagon secretion by slight sustained depolarization after closing the last few open K$_{ATP}$ channels. The depolarization inactivates the T-type Ca$^{2+}$ and Na$^+$ channels, thereby preventing Ca$^{2+}$ influx through the P/Q channels (upper right action potential) and glucagon release. Illustration based on Rorsman et al. 2012 (31).
reflect a direct tolbutamide stimulation of the a-cells that overwhelms indirect inhibition by somatostatin (65).

If the KATP channels are central for intrinsic a-cell recognition of glucose, channel knockout is expected to interfere with glucose regulation of glucagon release. Available data are conflicting also on this point. Whereas some studies found that the inhibitory effect of glucose is lost by KATP channel knockout (100,102), it was attenuated or essentially retained in other studies (65,103,104), and glucose inhibition of glucagon release was amplified when static inhibition of glucagon release by somatostatin was prevented by treating the KATP channel knockout islets with pertussis toxin (65).

There are also divergent opinions on the effect of glucose after chemical knockout of the KATP channels by exposure to high concentrations of tolbutamide, which prevented glucose inhibition of glucagon release in one study (92) but not in another two (40,91). At high concentrations of diazoxide, which maximally open the KATP channels to hyperpolarize the a-cells and inhibit glucagon release, glucose can still inhibit secretion further (39,65).

There are very different estimates of the KATP channel expression in a-cells. In situ hybridization data indicated higher channel density than in b-cells (105), whereas expression was 7-fold lower in the a-cells based on binding of the fluorescently labelled sulfonylurea glibenclamide (106). In accordance with the latter estimation the whole-cell KATP channel conductance in a-cells is only about 10% of that in b-cells (28,99). Another difference between the two cell types is that the smaller a-cells have 100-fold lower membrane conductance (25,28), making the membrane potential more sensitive to small currents. From this point of view it is surprising that exposure to high concentrations of diazoxide to activate all KATP channels and hyperpolarize islet cells eliminates Ca2+ signalling in all b-cells but often fails to completely shut off [Ca2+]i oscillations in a-cells (36,106). A possible interpretation is that a-cells have a more positive equilibrium potential for K+ and that hyperpolarization in response to KATP channel activation is insufficient for complete elimination of the action potentials that originate from membrane potentials of about −55 mV (28,29,93).

A fundamental aspect of the KATP channel hypothesis is that glucose depolarizes the a-cell, but it is, surprisingly, not settled how glucose affects the membrane potential. Diverging results have been obtained with invasive electrophysiological techniques with both depolarizing (93,100) and hyperpolarizing (28,105,107,108) effects of the sugar. The reason is probably that small stray currents associated with the invasive approach may significantly affect the membrane potential of the small a-cell with low membrane conductance (28). Inconsistent with the KATP channel hypothesis, membrane potential measurements with dye-based non-invasive technique indicate that glucose hyperpolarizes the a-cell (81,109).

Alternative interpretations of data supporting the KATP channel-centred model

The KATP channel-centred model provides an explanation why slight a-cell hyperpolarization with low concentrations of diazoxide (92,99) and slight depolarization with small elevations of extracellular K+ (100) stimulates and inhibits glucagon release, respectively. Although such elegant clarifications of counterintuitive responses may seem convincing, alternative interpretations of these and some other experiments will be discussed. Considering that a-cells show surprisingly low sensitivity to high concentrations of diazoxide (see above), it seems possible that low concentrations may preferentially act on b-cells to suppress somatostatin release and thus relieve some tonic inhibition of the a-cells. However, high concentrations of diazoxide likely inhibit glucagon release by hyperpolarizing the a-cells.

The Na+/K+-pumping ATPase is a major energy consumer in most types of cells and probably also in a-cells with much lower glucose-induced ATP production than b-cells (discussed above). Reduced Na+/K+ pumping may consequently underlie a more positive equilibrium potential for K+ in a- than in b-cells as speculated above. Moreover, if the energy utilization for ouabain-sensitive Na+/K+ pumping decreases with extracellular K+ elevation up to 14 mM like in squid axon (110), the inhibitory effect of small K+ elevations on glucagon release may be related to ATP elevation rather than to slight depolarization. This interpretation is consistent with a central role of metabolism in glucose-inhibited glucagon release without necessarily involving KATP channels.

Since the a-cell KATP channel activity is almost maximally inhibited in the absence of glucose (41), it is difficult to understand how low and high concentrations of tolbutamide can stimulate (92) and inhibit (31,41,92) glucagon release, respectively, if a-cell KATP channels were the sole target. The KATP channel-centred model offers no explanation for the stimulatory effect of low concentrations of tolbutamide (92). Stimulation is consistent with reports of a-cell depolarization with [Ca2+]i elevation after KATP channel closure by tolbutamide (40,81,91,111). However, in accordance with the KATP channel-centred model, it was instead the inhibitory effect of tolbutamide on glucagon release that was linked to a-cell depolarization after KATP channel closure (31,41,92). As discussed above, another study attributed tolbutamide inhibition of glucagon release to stimulated somatostatin secretion, since a high concentration of tolbutamide strongly stimulated glucagon release from somatostatin knockout islets (65).

Endoplasmic reticulum-dependent glucose inhibition of glucagon release

In most excitable cells depolarization underlies opening of voltage-dependent Ca2+ influx that triggers a cellular response. From this point of view one might expect that a-cells depolarize to release glucagon in the absence of glucose and that glucose elevation, contrary to the KATP-centred model, inhibits secretion by a-cell hyperpolarization. Although opinions differ about the glucose effect on a-cell membrane potential (see above), hyperpolarization seems to be the most common observation (28,81,105,107–109). The KATP channel-centred model is based on a special ion channel repertoire in a-cells that differs from that in b-cells, but the involvement of these channels in action potential generation does not
exclude that glucose inhibits glucagon release by hyperpolarizing α-cells. In β-cells, glucose elevation rapidly generates ATP (112) and slight depolarization (113) that coincides with lowering of [Ca\(^{2+}\)], (113,114), since ATP not only blocks K\(_{ATP}\) channels but also energizes the sarco(endo)plasmic reticulum Ca\(^{2+}\)-ATPase (SERCA-pump) to sequester Ca\(^{2+}\) in the endoplasmic reticulum (ER). It is not until the depolarization is sufficient to open voltage-dependent Ca\(^{2+}\) channels that (Ca\(^{2+}\)) increases (113) to trigger first-phase insulin secretion (115).

Similar glucose-induced lowering of [Ca\(^{2+}\)]\(_i\), by sequestration in the ER was early observed in guinea pig α-cells (116). Adrenaline, which in α-cells acts on α₁ and β-adrenergic receptors to generate inositol (1,4,5)-trisphosphate (IP₃) and cAMP, respectively (94), was found to raise [Ca\(^{2+}\)]\(_i\), by mobilizing the glucose-incorporated Ca\(^{2+}\) (116). The opposite effects on [Ca\(^{2+}\)]\(_i\) were therefore proposed to explain glucose inhibition and adrenaline stimulation of glucagon release (116). While this may seem to make sense, it is unlikely that ER sequestration of Ca\(^{2+}\) explains sustained inhibition of glucagon release, since the Ca\(^{2+}\) storage capacity is limited. However, the Ca\(^{2+}\) filling of the ER controls a store-operated depolarizing current in the plasma membrane that is at least partly carried by Ca\(^{2+}\) influx. In β- and α-cells the store-operated current is small, and alone it only causes modest [Ca\(^{2+}\)]\(_i\) elevation (81,117,118). Activation of the store-operated current by SERCA inhibition marginally elevates basal [Ca\(^{2+}\)]\(_i\) in β-cells (113), whereas α-cells react with a pronounced [Ca\(^{2+}\)]\(_i\), elevation involving also voltage-dependent Ca\(^{2+}\) entry (81) that stimulates glucagon release (40) and prevents (40) or reduces (100) inhibition by glucose. The likely reason for this difference is that the low membrane conductance of α-cells (28) makes the membrane potential sufficiently sensitive to small depolarizing currents that activate voltage-dependent Ca\(^{2+}\) influx. The high sensitivity to small currents is the basis for glucagon release control by store-operated glucose sensing in α-cells (40,81).

The store-operated Ca\(^{2+}\) influx in β-cells is inversely related to the Ca\(^{2+}\) content of the ER in a graded manner (118). Store-operated control of glucagon release from the α-cells implies that under hypoglycaemia, with little ATP to fuel the SERCA pump, there will be a net release of Ca\(^{2+}\) from the ER and activation of the depolarizing store-operated pathway, resulting in voltage-dependent Ca\(^{2+}\) influx and glucagon release (Figure 5). During return to normoglycaemia the SERCA pump is gradually more energized to fill the ER with Ca\(^{2+}\) and shut off the stimulatory cascade (40,81). Some important differences between α- and β-cells provide arguments in support of the store-operated mechanism. In β-cells 8–20 mM glucose is required to fill the ER (119–121), whereas maximum is reached at 3 mM in the α-cells (81). A similar difference is apparent when comparing the spatio-temporal kinetics of the ER Ca\(^{2+}\) sensor STIM1 and the plasma membrane Ca\(^{2+}\) channel protein Orai1, which are molecular components of the store-operated pathway. Emptying of ER Ca\(^{2+}\) induces STIM1 translocation from the ER to the plasma membrane where it co-clusters with Orai1 to activate the store-operated current in both α- and β-cells, and glucose reverses this process by stimulating re-translocation of STIM1 to the ER in a graded fashion, thus shutting off the store-operated current (122). In β-cells the re-translocation is saturated by 11–20 mM glucose, whereas only 3 mM is required in α-cells. Similar hypoglycaemia-like glucose concentrations consequently control glucagon release and the store-operated pathway in α-cells, whereas quite different concentrations control this pathway in β-cells. The simple idea that glucose inhibition and adrenaline stimulation of glucagon release are explained by stimulation of ER Ca\(^{2+}\) sequestration and release, respectively (116), obviously makes sense when the store-operated pathway is taken into account.

**Other α-cell mechanisms for glucose-inhibited glucagon release**

Like in store-operated control of glucagon release, another two hypotheses assume that glucose inhibits secretion by hyperpolarizing the α-cells to shut off voltage-dependent Ca\(^{2+}\) entry. Glucose-generated ATP was thus proposed to act by energizing the Na\(^+\)/K\(^+\) pump (123). In most types of cells the electrogenic effect of this pump is small (124) but may be significant in α-cells due to the their low membrane potential and small inactivating currents in the plasma membrane (125).
conductance (28). The other hypothesis is based on the observation that glucose elevations inhibiting glucagon secretion cause α-cell swelling (125) and activation of volume-regulated channels, leading to hyperpolarizing Cl⁻ influx (126,127). Another α-cell-intrinsic model is independent of the membrane potential and changes in [Ca²⁺], and focuses on the reduction of AMP that accompanies glucose-induced ATP elevation. The lowering of AMP is assumed to inhibit glucagon release by inactivating AMP-dependent protein kinase (AMPK) (34). Accordingly, activation of AMPK was found to stimulate glucagon release from a clonal α-cell line and mouse pancreatic islets, whereas a dominant-negative form of the kinase blocked the stimulatory effects of low glucose (34). However, knockout of the catalytic α1 sub-unit of AMPK instead sensitized glucagon secretion to the inhibitory action of glucose (128). Currently available data on the involvement of AMPK in glucose-regulated glucagon secretion therefore seem somewhat contradictory.

**Glucose stimulation of glucagon release**

Arguments that glucose inhibition of glucagon release from pancreatic islets depends on para- (76,77) and/or juxtacrine mechanisms (78) were obtained from observations that glucose instead stimulates glucagon release from purified α-cells. A major difference between isolated α-cells and those located within islets is that the latter show consistent [Ca²⁺] activity with oscillations at 1–3 mM glucose (36,77), whereas such activity is observed in less than 10% of isolated α-cells (81). Intra-islet location apparently stimulates the α-cells to induce [Ca²⁺], activity and glucagon release, which is a likely requirement for observing inhibition by glucose. The stimulation may involve autocrine α-cell factors (see above) that act in the narrow intercellular space of islets but whose effect is lost by dilution when studying purified or isolated α-cells. Indeed, increasing glucose in the 1–20 mM range concentration-dependently inhibits [Ca²⁺] oscillations in isolated α-cells, provided that they are already depolarized (40), which resembles the temporary inhibition of [Ca²⁺], signalling observed in islet-located α-cells after a 3–20 mM glucose elevation (36). Glucose-induced stimulation of glucagon release from purified α-cells is supposed to mirror that in β-cells with voltage-dependent [Ca²⁺] elevation due to depolarization by closure of KATP channels (76), which is opposite to the hyperpolarizing effect of glucose observed in most studies of isolated α-cells (28,81,105,107) or those located in situ within the islets (108,109). Also, glucagon release from pancreatic islets shows a stimulatory glucose component, since maximal inhibition at 5–7 mM is followed by a gradually reduced inhibition at higher concentrations (39–41) that transforms into stimulation above 20 mM of the sugar (Figure 1) (39). Even if closure of

---

**Figure 6.** Model for paracrine generation of pulsatile glucagon release in hyperglycaemia. The gap junction-coupled β-cells synchronize their Ca²⁺ oscillations with those of the non-coupled δ-cells and α-cells by releasing factors like ATP. Therefore, the Ca²⁺ oscillations in the δ-cells will generate pulsatile release of somatostatin in phase with that of insulin. Since somatostatin potently inhibits glucagon release with little effect on α-cell Ca²⁺, this inhibition will generate pulsatile glucagon release in opposite phase to insulin and somatostatin pulsatility. The lower left graphs show oscillations of the sub-plasma membrane Ca²⁺ concentration means (dark colour) ± SEM (light colour) of 6 β- and 13 α-cells within a single mouse islet (modified from Li et al. 2015 (36)), as well as an adapted recording from a δ-cell based on preliminary experiments. The graphs showing pulsatile secretion (lower right) are based on data from Hellman et al. 2009 (57).
the KATP channels were involved in the stimulatory effect of glucose on glucagon secretion from purified α-cells it seems unlikely that this mechanism accounts for stimulation by hyperglycaemic concentrations of the sugar, since the α-cell KATP channel activity is almost maximally inhibited already in the absence of glucose (41). The question arises whether another process than [Ca\(^{2+}\)]\(_i\), elevation may explain glucose stimulation. Since glucose inhibition of glucagon release is associated with a rather modest reduction of [Ca\(^{2+}\)]\(_i\), it is possible that secretion shows a greater dependence on amplifying factors and that Ca\(^{2+}\) has a more permissive role. Glucose-induced elevation of cAMP in α-cells has thus been suggested to underlie glucose stimulation of glucagon release (33), but available data on α-cell cAMP are so far limited.

**Conclusions**

A reason why glucose regulation of glucagon secretion is poorly understood is probably that experimental efforts have mostly been focused on finding a single mechanism. It has become increasingly evident that glucose has both inhibitory and stimulatory effects that act directly on the α-cell or indirectly via paracrine and/or juxtacrine signalling from other islet cell types. A further complication is that these mechanisms contribute differently depending on the prevailing glucose concentration. Under hypoglycaemic conditions α-cell-intrinsic glucose sensing and regulation of glucagon release is probably dominating. Although the two major hypotheses for such sensing seem incompatible in predicting that glucose inhibits glucagon secretion by either depolarizing (31,41,93,99,100) or hyperpolarizing (40,81) the α-cell, respectively, a model has been proposed that combines these mechanisms to explain the non-monotonic dependence of glucagon secretion on glucose (129). Most models for α-cell-intrinsic glucose regulation of glucagon release focus on Ca\(^{2+}\) as the trigger of secretion. However, one should also consider the possibility that Ca\(^{2+}\) has a more permissive role and that α-cell-intrinsic glucose regulation in terms of inhibition and stimulation is mediated by modulating factors like cAMP and perhaps diacylglycerol. This alternative is particularly attractive considering that glucose only modestly decreases α-cell [Ca\(^{2+}\)]\(_i\), signalling, which likely explains why even maximally inhibited glucagon secretion is only reduced to 25%–45% of maximal release (40,41). In hyperglycaemia paracrine factors become more important for glucose regulation of glucagon release, and the stimulated β-cells ultimately generate pulsatile secretion of the other islet hormones (Figure 6). Due to gap junction coupling they release insulin together with synchronizing paracrine factors like ATP in a co-ordinated pulsatile fashion to entrain the [Ca\(^{2+}\)]\(_i\), oscillation of the non-coupled δ- and α-cells into a common islet phase. The [Ca\(^{2+}\)]\(_i\) entrainment of β- and δ-cells likely explains the coinciding pulses of insulin and somatostatin release. However, the somatostatin pulses inhibit glucagon release despite peaks of α-cell [Ca\(^{2+}\)]\(_i\), thus clarifying how pulsatile glucagon release is synchronized in opposite phase α-cell [Ca\(^{2+}\)]\(_i\), as well as to pulsatile release of the other hormones. Since the stimulatory component of glucose on glucagon secretion increases with sugar concentration, multiple inhibitory processes may be required to ascertain dominating inhibition of glucagon secretion. Glucagon release in diabetes shows two distinct abnormalities—hypersecretion during hyperglycaemia and a failing secretory response to hypoglycaemia. Both abnormalities might be explained if the stimulatory glucose component is somehow amplified to dominate over the inhibitory mechanisms. The molecular events that underlie glucose stimulation of glucagon release should therefore be identified and explored as potential targets in diabetes therapy.

**Disclosure statement**

The author reports no conflicts of interest.

**Funding information**

This work was supported by grants from the Swedish Research Council (55X-06240) and the Swedish Diabetes Association (DIA2014-071, DIA2015-027).

**References**


79. Gromada J, Ma X, Hoy M, Bokvist K, Salehi A, Berggren PO, et al. ATP-sensitive K\(^+\) channel-dependent regulation of glucagon...


